What Is Changing
Risk and compliance functions assess exposure, challenge safeguards and escalate exceptions. Their findings inform decisions but do not grant new investment authority or assign responsibility for business benefits. Named executives must hold those responsibilities under approved delegations.
Where approvals permit, passing risk checks may support continued use within defined limits. Expansion requires an authorized decision on value, cost and ownership. Expected benefits cannot override mandatory safeguards.
Why It Matters
Imagine a manufacturer testing AI-supported maintenance. Trial safeguards pass review, and the business case forecasts fewer shutdowns. Yet plant operations has not accepted a downtime baseline, improvement target or review date. Controls are documented; the benefit commitment is not.
The investment sponsor defends the funding case, technology leaders manage delivery and risk teams challenge safeguard evidence. The plant operations executive owns changes to maintenance work and reports the result. Downtime may also fall because of scheduled repairs or replacement equipment.
The 6xD Reading
The AI Accountability Gap research connects three responsibilities in one dated accountability record: who can decide, who sponsors the investment and which executive owns the business result. It gives the next approval a named decision-maker and a testable commitment.
Viewed through 6xD Digital Cognitive Organization (D2), governance must follow how AI changes operating work and performance. The outcome owner should report against the accepted baseline, including costs, quality and adverse effects. Risk teams can challenge this evidence without taking responsibility for delivery.
Leadership Takeaway
At the next board or risk-committee review, select one material AI use seeking expansion. Request a dated record naming the authorized approver, investment sponsor and business outcome owner. Check the approved safeguards, agreed baseline and evidence required before further funding.
With no outcome owner, only an authorized approver may extend a limited trial within existing limits, assigning a corrective executive and review date. Unmet mandatory controls or absent approval require escalation. Management acts; the board challenges evidence.
Executive test: The AI controls passed. Who is authorized to expand the investment, and which executive must account for the result?
